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      Ulcerative Colitis (UC) is one type of inflammatory bowel disease (IBD). Herpes viruses have been 
suggested as possible etiological agents of UC and Crohn’s disease (CD). The aim of this study was to 
investigate the prevalence of Herpes Simplex virus (HSV), Cytomegalovirus (CMV) and Epstein-Barr virus 
(EBV) in patients with UC in comparison with healthy subjects by using PCR technique. In this analytical 
case-control study, five patients with UC and thirty healthy patients as controls were selected. Sampling was 
performed by endoscopic biopsy operation. Biopsy specimens were frozen under sterile conditions at -20˚C 
until analysis. After DNA extraction, analysis of PCR to detect HSV, CMV and EBV DNA in tissue samples 
was performed. Statistical analysis was performed with the χ
2
 test. We observed HSV DNA in 80% of UC 
samples (4 of 5) and 10% from the normal control group (3 of 30). CMV DNA was found in 80% of UC 
samples (4 of 5) and 30% from the normal control group (9 of 30). Also, EBV DNA was found in 60% of UC 
samples (3 of 5) and 36.7% from the normal control group (11 of 30). Statistical analysis showed a significant 
association between the prevalence of HSV and CMV and the incidence of UC compared with the control 
group. The results of the present study has shown UC patients have a predisposition to HSV and CMV 
infections as compared to healthy individuals. Also, the results demonstrate a lack of direct molecular 
evidence to support an association between HSV and CMV with UC.          
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INTRODUCTION 
     Inflammatory bowel disease (IBD) represents a 
group of idiopathic chronic inflammatory 
intestinal conditions. Patients with IBD are 
occasionally hospitalized due to fever, abdominal 
pain, and diarrhea, which are commonly attributed 
to an exacerbation of their underlying disease. 
Ulcerative colitis (UC) is a form of IBD that 
causes inflammation and ulcers in the colon. UC 
has an incidence of 1 to 20 cases per 100.000 
individuals per year, and a prevalence of 8 to 246 
per 100.000 individuals [1]. In recent years, cases 
of IBD associated with Herpes viruses infections 
have occasionally been reported [2-5]. Herpes 
Simplex virus (HSV), Cytomegalovirus (CMV) 
and Epstein-Barr virus (EBV) are ubiquitous 
Herpes viruses and establishes persistent 
infections in the host. HSV, CMV and EBV are 
transmitted through close personal contact with 
body fluids, including blood, urine, saliva, and 
also HSV, CMV and EBV infections can occur in 
immunocompromised patients such as recipients 
of organ transplants, patients undergoing 
hemodialysis, patients receiving 
immunosuppressive drugs, and patients with 
acquired immunedeficiency syndrome. In IBD 
patients, Herpes viruses have been recognized in 
colonoscopic biopsy specimens obtained during 
evaluation and management of IBD or diagnosed 
after pathologic examination of colon. However 
prospective studies examining prevalence of HSV, 
CMV and EBV genome in patients with IBD in 
comparison with a control population are limited. 
Patients with IBD treated with 
immunosuppressive agents including 
corticosteroids, cyclosporine, azathioprine and 
methotrexate, either alone or in combination. De 
Saussure et al. [6] treated 3 CMV-positive IBD 
cases with antiviral therapy, and only 1 patient got 
remission. Kandiel et al. [7] used antiviral drugs 
for the treatment of CMV positive colitis, and 
achieved a remission rate of 67-100%. 
Juffermans et al. [8] used antiviral drugs for the 
treatment of EBV positive colitis and showed 
 




azathioprine is an important drug in IBD patients. 
Give the importance of IBD as the unknown 
etiology and detection of an infectious agent in 
these patients might have important implications 
in treatment and prevention. The aim of the 
present study was to investigate the prevalence of 
HSV, CMV and EBV in patients with UC in 
comparison with healthy subjects by using PCR 
technique conducted. 
 
MATERIALS AND METHODS 
Patients 
     In this analytical case-control study, informed 
consent was received from all patients admitted 
to the Endoscopy clinic of Toos and Firoozgar 
hospital in Tehran, Iran between January 2013 
and June 2013. In this study, five patients with 
UC and thirty healthy patients as controls were 
sampled. Sampling was performed by 
endoscopic biopsy and a tissue sample size of 
25-50 mg was calculated for each patient. All 
collected tissues were kept frozen at -20ºC until 
analysis.   
DNA extraction  
     The DNA was extracted using the 
KiaSpin®Tissue Kit (Kiagen CA, Iran) 
according to the manufacture’s instructions. In 
order to determine the concentration of the 
sample absorbance at a wavelength to 260 nm 
was performed by biophotometer system 
(Eppendrof, Germany). In addition, to determine 
the purity of the sample wavelength of 280/260 
and 230/260 was also examined. 
PCR 
    We performed PCR amplification of the 
human β-globulin gene (Table 1) to determine 
the quality of extracted DNA [9]. The PCR 
amplification was performed in a 20 µL reaction 
volume contained 10 µL prime Taq premix (2x; 
Kiagen CA, Iran), 3 µL of sterile distilled water, 
1 µL of forward and reverse primers (TAG 
Copenhagen, Denmark), and 5 µL of DNA 
template. The PCR reaction was carried out as 
follows: an initial denaturation at 95ºC for 5 min, 
followed by 35 cycles at 95ºC for 50 sec, 55ºC 
for 45 sec, 72ºC for 40 sec and a final elongation 
at 72ºC for 5 min.  
Specific primers listed in Table 1 were used to 
reproduce the HSV genome of the samples [9]. 
For the reaction, the PCR mixture for a reaction 
volume of 20 µL consisted of 10 µL prime Taq 
premix (2x; Kiagen CA, Iran), 3 µL of sterile 
distilled water, 1 µL of forward and reverse 
primers (TAG Copenhagen, Denmark), and 5 µL 
of DNA template. The PCR reaction was carried 
out as follows: an initial denaturation at 95ºC for 
5 min, followed by 35 cycles at 95ºC for 50 sec, 
64ºC for 45 sec, 72ºC for 40 sec and a final 
elongation at 72ºC for 5 min. 
Specific primers listed in Table 1 were used to 
reproduce the CMV genome of the samples [9]. 
For the reaction, the PCR mixture for a reaction 
volume of 20 µL consisted of 10 µL prime Taq 
premix (2x; Kiagen CA, Iran), 3 µL of sterile 
distilled water, 1 µL of forward and reverse 
primers (TAG Copenhagen, Denmark), and 5 µL 
of DNA template. The PCR reaction was carried 
out as follows: an initial denaturation at 95ºC for 
5 min, followed by 35 cycles at 95ºC for 50 sec, 
60ºC for 45 sec, 72ºC for 40 sec and a final 
elongation at 72ºC for 5 min. 
We used specific primers to reproduce the EBV 
genome from the samples (Table 1) [9].
 
The 
mixture reaction PCR for a reaction volume of 
20 µL contained 10 µL prime Taq premix (2x; 
Kiagen CA, Iran), 3 µL of sterile distilled water, 
1 µL of forward and reverse primers (TAG 
Copenhagen, Denmark), and 5 µL of DNA 
template. The PCR reaction was carried out as 
follows: initial denaturation at 95ºC for 5 min, 
followed by 35 cycles at 95ºC for 40 sec, 65ºC 
for 40 sec, 72ºC for 40 sec and a final elongation 
at 72ºC for 5 min. Then, 5 µL of the PCR 
product was analyzed on a 1.5% agarose gel.  
Statistical analysis 
     Statistical analysis was performed using the 
SPSS-20 (SPSS, Inc., Chicago, IL, USA) 
software package. We used the t- and χ2 tests to 
analyze the relationship between the prevalence 
of HSV, CMV and EBV and occurrence of UC 
in addition to a comparison with control group 
tissue samples. Statistical significance was 
accepted at the 0.05 level. 
 
 
Table1. Primers sequences and base pair (bp) length 
Primer Sequence 
 (5´-3´) 
Size            
(bp) 

























EBV- R ACCTGGGAGGGCCATCGCAAGCTCC  
 





     HSV DNA was found in 80% of UC samples 
(4 of 5) and 10% from the normal control group 
(3 of 30). Statistical analysis showed a significant 
association between the prevalence of HSV and 
the incidence of UC compared to the control 
group (P= 0.003). 
CMV DNA was found in 80% of UC cases (4 of 
5) and 30% from the normal control group (9 of 
30). Statistical analysis showed a significant 
association between the prevalence of CMV and 
the incidence of UC compared to the control 
group (P= 0.03). EBV DNA was found in 60% 
of UC patients (3 of 5) and 36.7% from the 
normal control group (11 of 30). Statistical 
analysis showed no significant association 
between the prevalence of EBV and the 
incidence of UC compared to the control group 
(P= 0.36). We observed the highest prevalence                  
of HSV in UC patients older than 55 years     
(60%) of age and in the normal control 
participants who were 35-55 years of age (6.7%) 
(Table 2).      
The highest prevalence of CMV was observed in 
older than 55 years (60%) of age in UC patients 
and in two groups of normal control participants, 
those 35-55 years (13.3%) and under 35 years 
(13.3%) of age (Table 3).  
The highest prevalence of EBV was observed in 
older than 55 years (60%) of age in UC patients 
and in 35-55 years (16.6%) of age in the normal 
control group (Table 4). Statistical analysis 
showed no significant association between the 
prevalence of HSV, CMV and EBV in terms of 
age in patients with UC compared to the control 
group (P>0.05; Tables 2, 3 and 4).  
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Figure 1. PCR analysis of β-globulin. DNA extracted from tissue samples was amplified for β-globulin gene using primers 
described in Materials and Methods. Amplification yielded a band of 106 bp. As positive control (P), we used human DNA 
from fresh tissue; the negative control (N) was PCR master mix without DNA. Clinical samples, lanes 1-3. DNA molecular 
weight marker, M.                    
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Figure 2. PCR analysis for the detection of herpes simplex virus (HSV) from tissue samples. DNA extracted from tissues was 
amplified with specific primers. Amplification of fragment yielded a band of 465 bp. Positive control (P); negative control (N); 
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Figure 3. PCR analysis for the detection of Cytomegalovirus (CMV) from tissue samples. DNA extracted from tissues was 
amplified with specific primers. Amplification of fragment yielded a band of 167 bp. Positive control (P); negative control (N); 
clinical samples, lanes 1 and 2; DNA molecular weight marker, M.  
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Figure 4. PCR analysis for the detection of Epstein-Barr virus (EBV) from tissue samples. DNA extracted from tissues was 
amplified with specific primers. Amplification of fragment yielded a band of 102 bp. Positive control (P); negative control (N); 
clinical samples, lanes 1, 2 and 3; DNA molecular weight marker, M.  
 
 
Table 2. Clinical and pathological features of the UC and control group patients related to the presence of HSV 
Patients  HSV DNA  P value Total 
 Positive  Negative   
UC      
Age groups    >0.05  
Under 35 years 1 (20%)  1 (20%)  2 (40%) 
35-55 years 0 (0%)  0 (0%)  0 (0%) 
Over 55 years 3 (60%)  0 (0%)  3 (60%) 
Gender    >0.05  
Male 2 (40%)  1 (20%)  3 (60%) 
Female 2 (40%)  0 (0%)  2 (40%) 
Total 4 (80%)  1 (20%)  5 (100%) 
Control group      
Age groups    >0.05  
Under 35 years 1 (3.3%)  6 (20%)  7 (23.3%) 
35-55 years 2 (6.7%)  11 (37%)  13 (43.7%) 
Over 55 years 0 (0%)  10 (33%)  10 (33%) 
Gender    >0.05  
Male 1 (3.3%)  11 (37%)  12 (40.3%) 
Female 2 (6.7%)  16 (53%)  18 (59.7%) 














Table 3. Clinical and pathological features of the UC and control group patients related to the presence of CMV 
Patients  CMV DNA  P value Total 
 Positive  Negative   
UC      
Age groups    >0.05  
Under 35 years 1 (20%)  1 (20%)  2 (40%) 
35-55 years 0 (0%)  0 (0%)  0 (0%) 
Over 55 years 3 (60%)  0 (0%)  3 (60%) 
Gender    >0.05  
Male 2(40%)  1 (20%)  3 (60%) 
Female 2 (40%)  0 (0%)  2 (40%) 
Total 4 (80%)  1 (20%)  5 (100%) 
Control group      
Age groups    >0.05  
Under 35 years 4 (13.3%)  3(10%)  7 (23.3%) 
35-55 years 4 (13.3%)  9 (30%)  13 (43.3%) 
Over 55 years 1 (3.4%)  9 (30%)  10 (33.4%) 
Gender    >0.05  
Male 4 (13.4%)  8 (26.7%)  12 (40.1%) 
Female 5 (16.6%)  13 (43. 3%)  18 (59.9%) 
Total 9 (30%)  21 (70%)  30 (100%) 
 
 
Table 4. Clinical and pathological features of the UC and control group patients related to the presence of EBV 
  
Patients  EBV DNA  P value Total 
 Positive  Negative   
UC      
Age groups    >0.05  
Under 35 years 0 (0%)  0 (0%)  0 (0%) 
35-55 years 0 (0%)  2 (40%)  2 (40%) 
Over 55 years 3 (60%)  0 (0%)  3 (60%) 
Gender    >0.05  
Male 3 (60%)  0 (0%)  3 (60%) 
Female 0 (0%)  2 (40%)  2 (40%) 
Total 3 (60%)  2 (40%)  5 (100%) 
Control group      
Age groups    >0.05  
Under 35 years 4 (13.4%)  5 (16.6%)  9 (30%) 
35-55 years 5 (16.6%)  6 (20.1%)  11 (36.7%) 
Over 55 years 2 (6.7%)  8 (26.6%)  10 (33.3%) 
Gender    >0.05  
Male 3 (10.1%)  9 (30%)  12 (40.1%) 
Female 8 (26.6%)  10 (33.3%)  18 (59.9%) 
Total 11 (36.7%)  19 (63.3%)  30 (100%) 
 
In terms of gender, the highest prevalence of 
HSV was observed in both of two gender male 
(40%) and female (40%) in UC patients and in 
control group female (6.7%) (Table 2). Also, we 
observed the highest prevalence of CMV in 
both of two gender male (40%) and female 
(40%) in UC patients and in control group 
female (16.6%) (Table 3). We observed the 
highest prevalence of EBV in male UC patients 
(60%) and in normal control group female 
(26.6%) (Table 4). Statistical analysis showed 
no significant association between the 
prevalence of HSV, CMV and EBV and gender 
in UC patients compared to the control group 
(P>0.05; Tables 2, 3 and 4). In all tissue 
samples, we observed a 106 bp band that 
represented amplification of the human β-
globulin gene (Figure 1). Due to the quality and 
reliability of DNA extracted, PCR analysis with 
HSV specific primers was performed where we 
observed 465 bp bands that represented the 
replication (Figure 2). PCR analysis with CMV 
specific primers was performed where we 
observed 167 bp bands that represented the 
replication (Figure 3). PCR analysis with EBV 
specific primers was performed. A total of 102 
bp bands that represented the replication were 
observed (Figure 4). 
 





     In this study, we investigated UC and healthy 
tissues for the presence of HSV, CMV and EBV 
DNA by PCR method. In UC patients we 
detected HSV DNA in 80% of samples, CMV 
DNA in 80% of samples, and EBV DNA was 
detected in 60% of samples. In the control group, 
10% had HSV DNA, 30% had CMV DNA and 
36.7% had EBV DNA. There was an association 
between HSV and CMV presence and 
occurrence of UC compared to control group 
tissue.   
During recent years, a clear association between 
complicated courses of UC and the presence of 
Herpes viruses has been established. The exact 
pathogenic role of Herpes viruses in these 
patients remains unclear despite a great number 
of published reports. Powell et al. [10] first 
reported the association of CMV with UC in 
1961. However, the role of HSV, CMV and EBV 
in UC patients has not been reported in the 
literature in Iran till now. This is the first study to 
investigate the prevalence of HSV, CMV and 
EBV in UC patients in Iran. Herpes viruses 
infection in UC patients, especially in those who 
are immune-compromised by steroid therapy, 
can produce severe systemic disease and often 
leads to colectomy, but the coincidental 
diagnosis of UC and Herpes virus colitis have 
also been reported [11-13]. However, the 
importance of Herpes viruses as an exacerbating 
factor of UC is neglected by many clinicians. 
PCR has emerged as the most sensitive 
laboratorial method and immunohistochemistry 
or in situ hybridization has been reported for 
diagnosis of viral infection including that with 
Herpes viruses [2, 14-18]. In the current study 
has shown the presence of HSV, CMV and EBV 
in UC tissues and non-malignant by PCR method 
reflects the ability of the virus to infect of the 
different colon cells. In the study by Dimitroulia 
et al. [13] in the intestinal tissue CMV genome 
was detected in 32.9% of the IBD patients and 
only in 2.4% of the controls, also a significant 
association was detected between CMV intestinal 
infection and either UC or CD, although the 
association was even stronger for patients with 
UC. Hommes et al. [19] evaluated the 
pathogenicity of CMV in IBD; their results 
showed CMV causes significant clinical 
morbidity in IBD patients.  
Kishore et al. [14] investigated infection with 
CMV in patients with IBD, sixty-three patients 
with IBD (both UC and CD) were selected, 
results showed CMV infection in patients with 
IBD may be common, this has definite clinical 
significance and therefore should not be ignored. 
Although our results confirmed the results of 
Dimitroulia et al. [13], Hommes et al. [19] and 
Kishore et al. [14] indicating that there is 
association between CMV infection and 
progression of IBD. However, in other studies, 
no evidence of a direct association between IBD 
and CMV infection was found [12, 20].  
In the study by Yi et al. [12] on the prevalence 
and risk factors of CMV infection in IBD in 
Wuhan, central China, two hundred and twenty 
six IBD patients (189 UC and 37 patients with 
CD) were selected, CMV DNA was detected by 
nested PCR, their results showed no risk factor 
was found to be significantly correlated with 
CMV infection in risk factors analysis. Also, 
Leveque et al. [20] found no relationship 
between CMV viral load and disease severity in 
patients with active IBD. Although our results 
confirmed the results of Takeda et al. [21] 
indicating that EBV was found in biopsy 
specimens in patients with UC. However, our 
results are in stark contrast to other author’s data 
results that EBV and other herpes family viruses 
have been implicated in the pathogenesis of IBD 
[2, 3, 13, 15-17, 22]. Yanai et al. [17] found that 
EBV was detected in 63.3% of CD cases and 
60% of UC cases using in situ hybridization for 
EBV-encoded small RNA 1 (EBER-1), 
indicating that EBV infection may be related to 
IBD colonic diseases. Gehlert et al. [15] detected 
a large number of EBV infection in UC and CD 
patients tissue as compared to non-malignant 
cases of patients tissue. Ryan et al. [22] detected 
EBV DNA in 55% of CD and 64% of UC 
tissues, with mean viral loads significantly higher 
in these lesions than in normal colon tissues. 
Dimitroulia et al. [13] showed the prevalence of 
EBV was significantly higher in IBD patients 
than the controls tissue, the results showed EBV 
is associated with IBD.  
Bertalot et al. [2] showed a possible role of EBV 
in infection of UC patients. Kangro et al. [3] 
reported EBV infection was associated with UC. 
Also, Spieker and Herbst [16] have shown that 
EBV-positive lymphocytes accumulate in UC, 
suggesting the colon as a potential site for EBV 
replication and transmission in IBD patients. 
Although these results confirmed the other 
author’s results [2, 3, 13, 15-17, 22], indicating 
that the IBD exacerbation associated with EBV 
infection. 
 





     The results of the present study has shown 
UC patients have a predisposition to HSV and 
CMV infections as compared to healthy 
individuals.    
Also, the results demonstrate a lack of direct 
molecular evidence to support an association 
between HSV and CMV with UC.   
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